RASL-Seq CTC Assay
RASL-Seq CTC 检测
基本信息
- 批准号:8925136
- 负责人:
- 金额:$ 35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-10 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntigensBiological AssayBiological MarkersBiopsyCancer PatientCell CountCell LineCell SeparationCell TherapyCellsClinicalClinical assessmentsCytokeratinDetectionDevelopmentDiagnostic testsDoctor of MedicineDrug TargetingEmbryoEpithelialEvaluationFDA approvedGene ExpressionGene Expression ProfileGene Expression ProfilingGene TargetingGenesGovernmentHealthIndividualLegal patentLicensingLigationMarketingMeasurementMeasuresMediatingMesenchymalMessenger RNAMethodsMolecular ProfilingMonitorNeoplasm Circulating CellsNeoplasm MetastasisOncologistOutcomePTPRC genePatient CarePatientsPerformancePersonsPharmaceutical PreparationsPhasePopulationPredictive ValueProgression-Free SurvivalsRNAReagentRelapseResearchRiskSamplingSorting - Cell MovementTACSTD2 geneTechnologyTestingTherapeutic AgentsValidationadductbasecancer cellcompanion diagnosticscostdiagnostic assayestablished cell linegenome sequencingimprovedinnovationmalignant breast neoplasmminimally invasivenovel therapeuticsprognosticprogramsresponsesuccesstargeted sequencingtherapeutic targettranscriptome sequencing
项目摘要
DESCRIPTION (provided by applicant): This project will demonstrate the feasibility of identifying circulating tumor cells (CTCs) that have undergone an epithelial-mesenchymal transition (EMT) by profiling a gene expression signature using a targeted sequencing platform, the RASL-Seq assay. The presence of CTCs that have undergone EMT is prognostic of poor long term survival. The gene profile will also include genes for identifying and counting EpCAM+ and EpCAM- CTCs, and for identifying the expression of targets for therapeutic agents. Thus, the RASL-Seq CTC Profiling signature assay will deliver the EpCAM+ counts that the current Veridex CellSearch(R) assay does, but provide significant additional utility by identifying EpCAM- cells that have undergone EMT (not assessed by CellSearch) and which put the patient at risk, as well as provide the oncologist with an indication of what therapy these cells may be responsive to, overall significantly improving patient care and survival outcome. The EMT and risk signature used in this proposal is the subject of patents filed by MD Anderson. BioSpyder, which has separately licensed the RASL-Seq technology from UCSD, will demonstrate its feasibility in Phase I, determining if gene expression profiling of individual CTCs
is required or if pools of (e.g. EpCAM- and EpCAM+) CTCs can be used for testing. Initial development and validation will be with cell lines, then a set of 30 patient samples, and finally a
set of 200 patient samples. CellSearch results for these patients will be compared to the RASL-Seq assay results to determine the positive predictive value of the RASL-Seq test for Epcam+ CTCs. The results of this program will demonstrate that the RASL-Seq profiling assay has broad applicability not just to CTC analysis, but to analysis of biopsies, and for use as a companion diagnostic.
描述(由申请人提供):该项目将通过使用靶向测序平台RASL-Seq分析基因表达特征来证明识别经历了上皮-间充质转化(EMT)的循环肿瘤细胞(CTC)的可行性。接受EMT的CTC的存在预示着较差的长期存活率。基因图谱还将包括用于识别和计数EpCAM+和EpCAM-CTCs的基因,以及用于识别治疗剂靶标表达的基因。因此,RASL-Seq CTC Profiling Signature分析将提供当前Veridex CellSearch(R)分析所能提供的EpCAM+计数,但通过识别已接受EMT(未经CellSearch评估)并将患者置于危险境地的EpCAM-细胞,并为肿瘤学家提供这些细胞可能对何种治疗有效的指示,总体上显著改善患者的护理和生存结果。本提案中使用的EMT和风险签名是MD Anderson申请的专利的主题。BioSpyder已经从UCSD那里单独获得了RASL-Seq技术的许可,它将在第一阶段证明其可行性,即确定单个CTC的基因表达谱
或者(例如,EpCAM-和EpCAM+)CTC池是否可用于测试。最初的开发和验证将是细胞系,然后是一组30个患者样本,最后是
一组200个患者样本。这些患者的细胞搜索结果将与RASL-Seq测试结果进行比较,以确定RASL-Seq测试对Epcam+CTCs的阳性预测价值。该项目的结果将证明,RASL-Seq图谱分析不仅适用于CTC分析,而且还适用于活检组织的分析,并可用作辅助诊断。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRUCE E. SELIGMANN其他文献
BRUCE E. SELIGMANN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRUCE E. SELIGMANN', 18)}}的其他基金
TempO-LINC high throughput high sensitivity single cell gene expression profiling assay Ph II
TempO-LINC 高通量高灵敏度单细胞基因表达谱分析第二阶段
- 批准号:
10699784 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
TempO-LINC high throughput, high sensitivity single cell gene expression profiling assay
TempO-LINC 高通量、高灵敏度单细胞基因表达谱分析
- 批准号:
10156786 - 财政年份:2021
- 资助金额:
$ 35万 - 项目类别:
TempO-Vseq Screen for Genomic Risk of CAD Using Blood from a Finger Prick
使用手指采血进行 TempO-Vseq 筛查 CAD 基因组风险
- 批准号:
10080400 - 财政年份:2020
- 资助金额:
$ 35万 - 项目类别:
Functional Read-Out Enabling High Compound Throughput Toxicokinetic Assays
功能读出可实现高化合物通量毒代动力学测定
- 批准号:
10080462 - 财政年份:2020
- 资助金额:
$ 35万 - 项目类别:
Whole blood filter paper assay for Alzheimers Disease
全血滤纸检测阿尔茨海默病
- 批准号:
10823120 - 财政年份:2019
- 资助金额:
$ 35万 - 项目类别:
TempO-Seq Profiling of RNA Epitranscriptomic Modifications
RNA 表观转录组修饰的 TempO-Seq 分析
- 批准号:
9890040 - 财政年份:2018
- 资助金额:
$ 35万 - 项目类别:
TempO-Seq Profiling of RNA Epitranscriptomic Modifications
RNA 表观转录组修饰的 TempO-Seq 分析
- 批准号:
10220107 - 财政年份:2018
- 资助金额:
$ 35万 - 项目类别:
TempO-Seq Gene Expression Profiling of Intracellular Stained FACS Sorted Cells
细胞内染色 FACS 分选细胞的 TempO-Seq 基因表达谱
- 批准号:
9410000 - 财政年份:2016
- 资助金额:
$ 35万 - 项目类别:
Multiplexed mRNA and miRNA Profiling of Single Cells Phase II
单细胞 II 期多重 mRNA 和 miRNA 分析
- 批准号:
9356539 - 财政年份:2014
- 资助金额:
$ 35万 - 项目类别:
TempO-Seq for Preserved Tissues in Toxicity Testing Phase II
毒性测试第二阶段中保存组织的 TempO-Seq
- 批准号:
9202942 - 财政年份:2014
- 资助金额:
$ 35万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 35万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 35万 - 项目类别: